ProNAi – $158 Million IPO
San Diego – August 7, 2015 – Cooley advised the underwriters on ProNAi Therapeutics, Inc.'s $158.4 million initial public offering. ProNAi is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNA interference (DNAi) technology platform. Shares of the company's stock now trade on The NASDAQ Global Market under the symbol "DNAI."
Jefferies LLC and BofA Merrill Lynch acted as joint book-running managers for the offering. Wedbush PacGrow and SunTrust Robinson Humphrey acted as co-managers.
The Cooley corporate securities team representing the underwriters included partners Charlie Kim, David Peinsipp and Div Gupta and associates Kristin VanderPas, Dani Nazemian and Susan Walker.
About Cooley LLP
High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.